BioXcel Therapeutics Inc. priced an offering of 2 million common shares to raise $64 million.

The stocks will be sold at $32 each. BofA Securities, Canaccord Genuity and SunTrust Robinson Humphrey are the book-running managers for the offering, while H.C. Wainwright & Co. is the co-manager.

The New Haven, Conn.-based biopharmaceutical company granted underwriters a 30-day option to buy up to an additional 300,000 common shares.

The offering is expected to close around Feb. 24, BioXcel said in a Feb. 20 press release.